Ask Warren

Adbiotech

179530 · KOSDAQ · ₩179530 · 애드바이오텍

₩1,930▲ ₩21 (1.10%)End-of-day · Oct 29, 2026 · End-of-day prices.
Trade
Alert me
SellBuy
AnnualQuarterly

Income statement

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Revenue₩2.9B₩3.1B₩3B₩3.6B₩2.8B₩3.5B₩4.6B₩1.7B
Cost of sales₩1.5B₩1.6B₩1.8B₩2.6B₩1.7B₩1.7B₩3B₩1.2B
Gross profit₩1.4B₩1.5B₩1.2B₩1.1B₩1.1B₩1.8B₩1.6B₩546M
Operating income−₩1.9B−₩1.1B₩346M−₩1.8B−₩1.9B−₩200M−₩723M−₩1.1B
Net income₩5.1B−₩5.4B₩1.5B₩51M−₩4.3B−₩601M−₩7.7B₩1.1B
Net income to shareholders−₩279M−₩5.4B₩7B−₩4.8B−₩5.1B−₩368M−₩762M−₩1.1B

Balance sheet

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Total assets₩54B₩43B₩48B₩28B₩23B₩25B₩23B₩22B
Current assets₩25B₩12B₩21B₩15B₩9.7B₩11B₩8.4B₩7B
Cash and equivalents₩12B₩4.9B₩3.9B₩2.1B₩2.4B₩620M₩639M₩638M
Total liabilities₩27B₩29B₩35B₩27B₩20B₩20B₩20B₩19B
Current liabilities₩23B₩26B₩31B₩24B₩16B₩15B₩15B₩14B
Borrowings₩15B₩13B₩17B₩10B₩12B₩12B₩11B₩11B
Total equity₩26B₩14B₩14B₩14M₩2.3B₩5.4B₩3B₩2.7B
Shareholders' equity₩28B₩15B₩15B₩1.8B₩4.1B₩7.5B₩4.8B₩4.4B

Cash flow

Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024
Cash from operations−₩2.8B₩1.6B−₩144M₩567M−₩1.2B−₩533M−₩1B−₩1.6B
Capital spending₩88M₩50M₩154M₩87M₩120M₩17M₩18M₩105M
Free cash flow−₩2.9B₩1.5B−₩298M₩481M−₩1.3B−₩550M−₩1B−₩1.7B

Consolidated where available. Amounts in won.

Also known as: Adbiotech / 애드바이오텍 / 179530 / KRX:179530

Source: KRX statistical information